- Home
- PULM vs IBIO Comparison
PULM vs IBIO Comparison
Compare PULM & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- IBIO
- Stock Information
- Founded
- PULM 2003
- IBIO 2008
- Country
- PULM United States
- IBIO United States
- Employees
- PULM N/A
- IBIO N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- IBIO Health Care
- Exchange
- PULM Nasdaq
- IBIO Nasdaq
- Market Cap
- PULM 18.3M
- IBIO 16.4M
- IPO Year
- PULM N/A
- IBIO N/A
- Fundamental
- Price
- PULM N/A
- IBIO $0.87
- Analyst Decision
- PULM
- IBIO Strong Buy
- Analyst Count
- PULM 0
- IBIO 2
- Target Price
- PULM N/A
- IBIO $5.50
- AVG Volume (30 Days)
- PULM 17.8K
- IBIO 376.3K
- Earning Date
- PULM 11-07-2025
- IBIO 11-11-2025
- Dividend Yield
- PULM N/A
- IBIO N/A
- EPS Growth
- PULM N/A
- IBIO N/A
- EPS
- PULM N/A
- IBIO N/A
- Revenue
- PULM $369,000.00
- IBIO $400,000.00
- Revenue This Year
- PULM N/A
- IBIO N/A
- Revenue Next Year
- PULM $134.88
- IBIO N/A
- P/E Ratio
- PULM N/A
- IBIO N/A
- Revenue Growth
- PULM N/A
- IBIO 77.78
- 52 Week Low
- PULM $1.96
- IBIO $0.56
- 52 Week High
- PULM $10.40
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- PULM 47.11
- IBIO 60.39
- Support Level
- PULM $4.45
- IBIO $0.78
- Resistance Level
- PULM $5.50
- IBIO $0.86
- Average True Range (ATR)
- PULM 0.26
- IBIO 0.04
- MACD
- PULM 0.02
- IBIO 0.00
- Stochastic Oscillator
- PULM 38.53
- IBIO 95.55
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.